Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 6/20 | 0.51 |
| ▸ | MC5R | P33032 | 2/20 | 0.51 |
| ▸ | MC3R | P41968 | 2/20 | 0.51 |
| ▸ | MC1R | Q01726 | 2/20 | 0.51 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.50 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.49 |
| ▸ | CTSS | P25774 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.49 |
| ▸ | CTSH | P09668 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22969135 | 0.91 | NMUR2 (0.50) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL22969109 | 0.90 | NMUR2 (0.49) | IL23RMC4RMC5RMC3RMC1R | |
| SCHEMBL22969060 | 0.88 | IL23R (0.57) | IL23RMC4R | |
| SCHEMBL22968955 | 0.88 | IL23R (0.57) | IL23RMC4R | |
| SCHEMBL22969148 | 0.88 | IL23R (0.56) | IL23RMC4R | |
| SCHEMBL22969250 | 0.87 | IL23R (0.58) | IL23R | |
| SCHEMBL22969132 | 0.87 | IL23R (0.60) | IL23RCXCR4 | |
| SCHEMBL22969055 | 0.83 | IL23R (0.65) | IL23RCXCR4 | |
| SCHEMBL22969124 | 0.82 | IL23R (0.64) | IL23R | |
| SCHEMBL22969245 | 0.82 | IL23R (0.56) | IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210038737-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11793884-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | IL23R 4090/4885MC4R 2826/4885MC5R 3895/4885 |
| US-20210038737-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | IL23R 4090/4885MC4R 2826/4885MC5R 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.